Novel approaches to incorporating pharmacoeconomic studies into phase III clinical trials for Alzheimer's disease

Journal of Nutrition, Health and Aging

Volumn 14, Issue 8, 2010, Pages 640-647

  Fillit, H ^a,b   Cummings, J ^c   Neumann, P ^d   McLaughlin, T ^e   Salavtore, P ^f   Leibman, C ^e  

^a Alzheimers Drug Discovery Foundation   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas   (United States)

^d TUFTS MEDICAL CENTER   (United States)

^e Farallon Capital Management   (United States)

^f Health Business Communications   (United States)

Author keywords

aging; Alzheimer's disease; clinical trials; co morbidity; comparative effectiveness; cost effectiveness; dementia; Health economics; health policy; pharmacoeconomics; regulatory approval

Indexed keywords

DONEPEZIL;

ALZHEIMER DISEASE; CLINICAL TRIAL; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; MORBIDITY; OUTCOME ASSESSMENT; PATIENT CARE; POWER ANALYSIS; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW;

EID: 77957894706     PISSN: 12797707     EISSN: 17604788     Source Type: Journal    
DOI: 10.1007/s12603-010-0310-8     Document Type: Review

References (84)

1. 2009 Alzheimer's disease facts and figures. Alzheimers Dement 2009;5:234-270.
2. A. Wimo B. Winblad L. Jonsson 2010 The worldwide societal costs of dementia: Estimates for 2009 Alzheimers Dement 6 98 103 10.1016/j.jalz.2010.01. 010 20298969
3. L.M. Refolo H.M. Fillit 2006 Partnerships between philanthropy, government and industry are needed to advance drug discovery for neurodegenerative diseases Curr Alzheimer Res 3 175 176 10.2174/ 156720506777632853 16842090 (Pubitemid 43988127)
4. S.D. Pearson M.D. Rawlins 2005 Quality, innovation, and value for money: NICE and the British National Health Service JAMA 294 2618 2622 10.1001/jama.294.20.2618 16304076 (Pubitemid 41697251)
5. N. Freemantle M.F. Drummond 2010 AHRQ Series Commentary 3: The United States addresses comparative effectiveness but not cost-effectiveness through the Effective Health-Care Program J Clin Epidemiol 63 479 480 10.1016/j.jclinepi.2010.01.008 20346862
6. S.L. Aspinall C.B. Good P.A. Glassman M.A. Valentino 2005 The evolving use of cost-effectiveness analysis in formulary management within the Department of Veterans Affairs Med Care 43 20 26 10.1097/01.mlr.0000170004.17480.49 16056005
7. D.A. Henry S.R. Hill A. Harris 2005 Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme JAMA 294 2630 2632 10.1001/jama.294.20.2630 16304078 (Pubitemid 41697253)
8. P.J. Neumann A.B. Rosen M.C. Weinstein 2005 Medicare and cost-effectiveness analysis N Engl J Med 353 1516 1522 10.1056/NEJMsb050564 16207857 (Pubitemid 41400929)
9. E.M. Schwam S. Abu-Shakra del V.M. R.J. Townsend M.C. Carrillo H. Fillit 2007 Health economics and the value of therapy in Alzheimer's disease Alzheimers Dement 3 143 151 10.1016/j.jalz.2007.04.391 19595929 (Pubitemid 46825518)
10. P.J. Neumann 2000 Estimating the long-term cost savings from the treatment of Alzheimer's disease: a modelling approach Pharmacoeconomics 17 109 10.2165/00019053-200017010-00007 10747762
11. P.J. Neumann C.H. Fang J.T. Cohen 2009 30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement Pharmacoeconomics 27 861 872 10.2165/11312720-000000000-00000 19803540
12. P.J. Neumann R.C. Hermann P.A. Berenbaum M.C. Weinstein 1997 Methods of cost-effectiveness analysis in the assessment of new drugs for Alzheimer's disease Psychiatr Serv 48 1440 1444 9355172
13. H. Fillit J.W. Hill R. Futterman 2002 Health care utilization and costs of Alzheimer's disease: the role of co-morbid conditions, disease stage, and pharmacotherapy Fam Med 34 528 535 12144008
14. C. Bombardier A. Maetzel 1999 Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies? Ann Rheum Dis 58 Suppl1 I82 I85 10.1136/ard.58.2008.i82 10577979
15. D.A. Revicki L. Frank 1999 Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies Pharmacoeconomics 15 423 434 10.2165/00019053-199915050-00001 10537960 (Pubitemid 29210946)
16. R.A. Rosenheck D.L. Leslie J.L. Sindelar, et al. 2007 Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease Arch Gen Psychiatry 64 1259 1268 10.1001/archpsyc.64.11.1259 17984395 (Pubitemid 350074824)
17. T.D. Szucs B. Waeber Y. Tomonaga 2010 Cost-effectiveness of antihypertensive treatment in patients 80 years of age or older in Switzerland: an analysis of the HYVET study from a Swiss perspective J Hum Hypertens 24 117 123 10.1038/jhh.2009.47 19536166
18. C. Courtney D. Farrell R. Gray, et al. 2004 Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial Lancet 363 2105 2115 10.1016/S0140-6736(04)16499-4 15220031 (Pubitemid 38844150)
19. L.S. Schneider 2004 AD2000: donepezil in Alzheimer's disease Lancet 363 2100 2101 10.1016/S0140-6736(04)16533-1 15220027 (Pubitemid 38844146)
20. S. Ramsey R. Willke A. Briggs, et al. 2005 Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report Value Health 8 521 533 10.1111/j.1524-4733.2005.00045.x 16176491 (Pubitemid 41727304)
21. S.D. Reed K.J. Anstrom A. Bakhai, et al. 2005 Conducting economic evaluations alongside multinational clinical trials: toward a research consensus Am Heart J 149 434 443 10.1016/j.ahj.2004.11.001 15864231 (Pubitemid 40585405)
22. M.A. Hlatky D.K. Owens G.D. Sanders 2006 Cost-effectiveness as an outcome in randomized clinical trials Clin Trials 3 543 551 10.1177/1740774506073105 17170039
23. A. Tsuchiya 2000 QALYs and ageism: philosophical theories and age weighting Health Econ 9 57 68 10.1002/(SICI)1099-1050(200001)9:1<57::AID- HEC484>3.0.CO;2-N 10694760 (Pubitemid 30079626)
24. M.N. Kane 2002 Awareness of ageism, motivation, and countertransference in the care of elders with Alzheimer's disease Am J Alzheimers Dis Other Demen 17 101 109 10.1177/153331750201700206 11954668
25. F.T. Sherman 2003 Baby Boomer senators must face their own dismal future! Senate hearing confirms that ageism in healthcare flourishes Geriatrics 58 10
26. M.A. McDowall 2006 Ageism in services for transient ischaemic attack and stroke: ageism or cost-benefit analysis? BMJ 333 656 10.1136/bmj.333.7569.656-b 16990338
27. E. Bodner 2009 On the origins of ageism among older and younger adults Int Psychogeriatr 21 1003 1014 10.1017/S104161020999055X 19619389
28. H. Fillit D.T. Nash D. Shineman 2009 Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Primary prevention of dementia in Alzheimer's disease: a perspective from prevention research in cardiovascular disease and stroke Alzheimers Dement 5 149 153 10.1016/j.jalz.2009.01.012 19328448
29. P.J. Neumann E.A. Sandberg S.S. Araki K.M. Kuntz D. Feeny M.C. Weinstein 2000 A comparison of HUI2 and HUI3 utility scores in Alzheimer's disease Med Decis Making 20 413 422 10.1177/0272989X0002000405 11059474
30. P.J. Neumann 2005 Health utilities in Alzheimer's disease and implications for costeffectiveness analysis Pharmacoeconomics 23 537 541 10.2165/00019053-200523060-00002 15960551 (Pubitemid 40994123)
31. C.W. Zhu C. Leibman T. McLaughlin, et al. 2008 Patient dependence and longitudinal changes in costs of care in Alzheimer's disease Dement Geriatr Cogn Disord 26 416 423 10.1159/000164797 18946219
32. C.W. Zhu C. Leibman T. McLaughlin, et al. 2008 The effects of patient function and dependence on costs of care in Alzheimer's disease J Am Geriatr Soc 56 1497 1503 10.1111/j.1532-5415.2008.01798.x 18662215
33. J. Hill H. Fillit S.K. Thomas S. Chang 2006 Functional impairment, healthcare costs and the prevalence of institutionalisation in patients with Alzheimer's disease and other dementias Pharmacoeconomics 24 265 280 10.2165/00019053-200624030-00006 16519548 (Pubitemid 43374378)
34. L. Torian E. Davidson G. Fulop L. Sell H. Fillit 1992 The effect of dementia on acute care in a geriatric medical unit Int Psychogeriatr 4 231 239 10.1017/S1041610292001066 1477311
35. H. Fillit J.W. Hill R. Futterman 2002 Health care utilization and costs of Alzheimer's disease: the role of co-morbid conditions, disease stage, and pharmacotherapy Fam Med 34 528 535 12144008
36. H. Fillit J. Hill 2005 Economics of dementia and pharmacoeconomics of dementia therapy Am J Geriatr Pharmacother 3 39 49 10.1016/j.amjopharm.2005.03. 005 16089246 (Pubitemid 41122357)
37. S. Lu J. Hill H. Fillit 2005 Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study Am J Geriatr Pharmacother 3 92 102 10.1016/j.amjopharm.2005.07.001 16129386 (Pubitemid 41200511)
38. T. Voisin S. Andrieu C. Cantet B. Vellas 2010 Predictive Factors of Hospitalizations in Alzheimer's Disease: A Two-Year Prospective Study in 686 Patients of the REAL.FR Study J Nutr Health Aging 14 288 291 10.1007/s12603-010-0063-4 20305996
39. Y. Zhao T.C. Kuo S. Weir M.S. Kramer A.S. Ash 2008 Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's BMC Health Serv Res 8 108 10.1186/1472-6963-8-108 18498638 (Pubitemid 351840944)
40. G. Fillenbaum A. Heyman B.L. Peterson C.F. Pieper A.L. Weiman 2001 Use and cost of hospitalization of patients with AD by stage and living arrangement: CERAD XXI Neurology 56 201 206 11160956
41. L. Jonsson J.M. Eriksdotter L. Kilander, et al. 2006 Determinants of costs of care for patients with Alzheimer's disease Int J Geriatr Psychiatry 21 449 459 10.1002/gps.1489 16676288
42. A. Wimo B. Winblad K. Engedal, et al. 2003 An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial Dement Geriatr Cogn Disord 15 44 54 10.1159/000066669 12457078 (Pubitemid 35404261)
43. H. Feldman S. Gauthier J. Hecker, et al. 2004 Economic evaluation of donepezil in moderate to severe Alzheimer disease Neurology 63 644 650 15326236
44. S. Lu J. Hill H. Fillit 2005 Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study Am J Geriatr Pharmacother 3 92 102 10.1016/j.amjopharm.2005.07.001 16129386 (Pubitemid 41200511)
45. R.C. Mohs J. Schmeidler M. Aryan 2000 Longitudinal studies of cognitive, functional and behavioural change in patients with Alzheimer's disease Stat Med 19 1401 1409 10.1002/(SICI)1097-0258(20000615/30)19:11/12<1401::AID- SIM432>3.0.CO;2-X 10844705
46. R.C. Mohs R.S. Doody J.C. Morris, et al. 2001 A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients Neurology 57 481 488 11502917
47. J. Hill H. Fillit S.K. Thomas S. Chang 2006 Functional impairment, healthcare costs and the prevalence of institutionalisation in patients with Alzheimer's disease and other dementias Pharmacoeconomics 24 265 280 10.2165/00019053-200624030-00006 16519548 (Pubitemid 43374378)
48. L. Torian E. Davidson G. Fulop L. Sell H. Fillit 1992 The effect of dementia on acute care in a geriatric medical unit Int Psychogeriatr 4 231 239 10.1017/S1041610292001066 1477311
49. W.C. McCormick J. Hardy W.A. Kukull, et al. 2001 Healthcare utilization and costs in managed care patients with Alzheimer's disease during the last few years of life J Am Geriatr Soc 49 1156 1160 10.1046/j.1532-5415.2001.49231.x 11559373 (Pubitemid 32900141)
50. C.R. Jack Jr. D.S. Knopman W.J. Jagust, et al. 2010 Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol 9 119 128 10.1016/S1474-4422(09)70299-6 20083042
51. J.L. Cummings 2009 Defining and labeling disease-modifying treatments for Alzheimer's disease Alzheimers Dement 5 406 418 10.1016/j.jalz.2008.12.003 19751920
52. S. Salloway R. Sperling S. Gilman, et al. 2009 A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease Neurology 73 2061 2070 10.1212/WNL.0b013e3181c67808 19923550
53. M. Drummond M. Barbieri J. Cook, et al. 2009 Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report Value Health 12 409 418 10.1111/j.1524-4733.2008.00489.x 19900249
54. P.A. Clark D.M. Bass W.J. Looman C.A. McCarthy S. Eckert 2004 Outcomes for patients with dementia from the Cleveland Alzheimer's Managed Care Demonstration Aging Ment Health 8 40 51 10.1080/13607860310001613329 14690867 (Pubitemid 38155632)
55. C.M. Callahan M.A. Boustani F.W. Unverzagt, et al. 2006 Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: a randomized controlled trial JAMA 295 2148 2157 10.1001/jama.295.18.2148 16684985
56. D.L. Cherry B.G. Vickrey L. Schwankovsky E. Heck M. Plauchm R. Yep 2004 Interventions to improve quality of care: the Kaiser Permanente-alzheimer's Association Dementia Care Project Am J Manag Care 10 553 560 15352531
57. K.E. Covinsky C.B. Johnston 2006 Envisioning better approaches for dementia care Ann Intern Med 145 780 781 17116923
58. M. Lessig J. Farrell E. Madhavan, et al. 2006 Cooperative dementia care clinics: A new model for managing cognitively impaired patients J Am Geriatr Soc 54 1937 1942 10.1111/j.1532-5415.2006.00975.x 17198502 (Pubitemid 44915840)
59. M.S. Mittelman S.H. Ferris E. Shulman G. Steinberg B. Levin 1996 A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trial JAMA 276 1725 1731 10.1001/jama.276.21. 1725 8940320
60. L.S. Schneider M. Sano 2009 Current Alzheimer's disease clinical trials: methods and placebo outcomes Alzheimers Dement 5 388 397 10.1016/j.jalz.2009.07. 038 19751918
61. J. Puterman D.A. Alter 2009 The application of disease management to clinical trial designs Popul Health Manag 12 205 208 10.1089/pop.2008.0040 19663623
62. H. Fillit D. Knopman J. Cummings F. Appel 1999 Opportunities for improving managed care for individuals with dementia: Part 2-A framework for care Am J Manag Care 5 317 324 10351028 (Pubitemid 29138290)
63. H.M. Fillit R.S. Doody K. Binaso, et al. 2006 Recommendations for best practices in the treatment of Alzheimer's disease in managed care Am J Geriatr Pharmacother 4 SupplA S9 S24 10.1016/j.amjopharm.2006.10.001 17157793 (Pubitemid 44848197)
64. P.V. Rabins D. Blacker B.W. Rovner, et al. 2007 American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias Am J Psychiatry 164 5 56 18340692
65. L.O. Nichols C. Chang A. Lummus, et al. 2008 The cost-effectiveness of a behavior intervention with caregivers of patients with Alzheimer's disease J Am Geriatr Soc 56 413 420 10.1111/j.1532-5415.2007.01569.x 18179480 (Pubitemid 351327921)
66. M.S. Mittelman W.E. Haley O.J. Clay D.L. Roth 2006 Improving caregiver well-being delays nursing home placement of patients with Alzheimer disease Neurology 67 1592 1599 10.1212/01.wnl.0000242727.81172.91 17101889 (Pubitemid 44747929)
67. J.P. Hirdes G. Ljunggren J.N. Morris, et al. 2008 Reliability of the interRAI suite of assessment instruments: a 12-country study of an integrated health information system BMC Health Serv Res 8 277 10.1186/1472-6963-8-277 19115991
68. L.C. Gray R. Bernabei K. Berg, et al. 2008 Standardizing assessment of elderly people in acute care: the interRAI Acute Care instrument J Am Geriatr Soc 56 536 541 10.1111/j.1532-5415.2007.01590.x 18179498 (Pubitemid 351327942)
69. California workgroup for Alzheimer's disease management. Guidelines for Alzheimer's disease management. 2008. http://www.caalz.org/PDF-files/Guideline- FullReport-CA.pdf. Access June 11, 2010
70. Workgroup on Alzheimer's disease and other dementias. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias. 2010. American Psychiatric Association. http://www.psychiatryonline.com/ pracGuide/PracticePDFs/AlzPG101007.pdf. Accessed June 11, 2010.
71. T.C. Kuo Y. Zhao S. Weir M.S. Kramer A.S. Ash 2008 Implications of comorbidity on costs for patients with Alzheimer disease Med Care 46 839 846 10.1097/MLR.0b013e318178940b 18665064
72. D.C. Malone T.P. McLaughlin P.M. Wahl, et al. 2009 Burden of Alzheimer's disease and association with negative health outcomes Am J Manag Care 15 481 488 19670951
73. J.W. Hill R. Futterman S. Duttagupta V. Mastey J.R. Lloyd H. Fillit 2002 Alzheimer's disease and related dementias increase costs of comorbidities in managed Medicare Neurology 58 62 70 11781407
74. S. Chhatre M.G. Weiner R. Jayadevappa J.C. Johnson 2009 Incremental burden of congestive heart failure among elderly with Alzheimer's Aging Ment Health 13 628 634 10.1080/13607860902774469 19629789
75. J.P. Bynum P.V. Rabins W. Weller M. Niefeld G.F. Anderson A.W. Wu 2004 The relationship between a dementia diagnosis, chronic illness, medicare expenditures, and hospital use J Am Geriatr Soc 52 187 194 10.1111/j.1532-5415. 2004.52054.x 14728626 (Pubitemid 38233479)
76. S. Arlt R. Lindner A. Rosler W. von Renteln-Kruse 2008 Adherence to medication in patients with dementia: predictors and strategies for improvement Drugs Aging 25 1033 1047 10.2165/0002512-200825120-00005 19021302
77. K. Insel D. Morrow B. Brewer A. Figueredo 2006 Executive function, working memory, and medication adherence among older adults J Gerontol B Psychol Sci Soc Sci 61 102 107
78. S.J. Wang H.M. Hung R.T. O'Neill 2009 Adaptive patient enrichment designs in therapeutic trials Biom J 51 358 374 10.1002/bimj.200900003 19358222
79. J.L. Cummings 2008 Controversies in Alzheimer's disease drug development Int Rev Psychiatry 20 389 395 10.1080/09540260802094548 18925488
80. K. Insel D. Morrow B. Brewer A. Figueredo 2006 Executive function, working memory, and medication adherence among older adults J Gerontol B Psychol Sci Soc Sci 61 102 107
81. J.L. Cummings 2006 Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials Alzheimers Dement 2 263 271 10.1016/j.jalz.2006.07.001 19595897 (Pubitemid 44524773)
82. A. Finckh N. Bansback M.H. Liang 2010 Cost-effectiveness of biologics in early rheumatoid arthritis Ann Intern Med 152 333 334 20194244
83. M. Boers 2009 Cost-effectiveness of biologics as first-line treatment of rheumatoid arthritis: case closed? Ann Intern Med 151 668 669 19884628
84. J.O. Rinne D.J. Brooks M.N. Rossor, et al. 2010 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study Lancet Neurol 9 363 372 10.1016/S1474-4422(10)70043-0 20189881